Darzalex (daratumumab) / Genmab, J&J  >>  Phase 3
Welcome,         Profile    Billing    Logout  

39 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Darzalex (daratumumab) / J&J
CASTOR, NCT02136134 / 2014-000255-85: Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Checkmark 4-year update of efficacy and safety data from CASTOR trial for multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: 4-year update of efficacy and safety data from CASTOR trial for multiple myeloma at ASH 2019
Checkmark From CASTOR for RRMM at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: From CASTOR for RRMM at ASH 2018 [screenshot]
Checkmark From CASTOR for RRMM at ASH 2017 [screenshot]
More
Completed
3
498
Europe, US, RoW
Daratumumab, VELCADE (Bortezomib), VELCADE, Dexamethasone
Janssen Research & Development, LLC
Multiple Myeloma
01/16
01/24
ALCYONE, NCT02195479 / 2014-002272-88: A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Checkmark First OS results from the ALCYONE study in 1L multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: First OS results from the ALCYONE study in 1L multiple myeloma at ASH 2019
Checkmark OS data from ALCYONE trial in combination with Velcade for multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: OS data from ALCYONE trial in combination with Velcade for multiple myeloma at ASH 2019
Checkmark ALCYONE data in previously untreated multiple myeloma at ASH 2018 [screenshot]
More
Active, not recruiting
3
706
Europe, Japan, US, RoW
Velcade, Melphalan, Prednisone, Daratumumab IV, Dexamethasone, Daratumumab SC
Janssen Research & Development, LLC
Multiple Myeloma
11/17
07/24
MAIA, NCT02252172 / 2014-002273-11: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Checkmark Data from MAIA trial in combination with Revlimid for multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from MAIA trial in combination with Revlimid for multiple myeloma at ASH 2022
Checkmark From MAIA trial in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma at EHA 2021
Jun 2021 - Jun 2021: From MAIA trial in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma at EHA 2021
Checkmark Data from trial in combination with Revlimid for multiple myeloma at ASH 2020
More
Active, not recruiting
3
737
Europe, Canada, US, RoW
Daratumumab IV, JNJ-54767414, Lenalidomide, Dexamethasone, Daratumumab SC
Janssen Research & Development, LLC
Multiple Myeloma
09/18
09/24
2018-004330-15: A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethasone for relapsed multiple myeloma Étude de phase III randomisée, multicentrique, comparant l’administration continue ou pour une durée fixe de l’association daratumumab, lenalidomide et dexaméthasone dans le myélome multiple en rechute

Not yet recruiting
3
434
Europe
Daratumumab, Lenalidomide, Dexamethasone, Solution for infusion, Capsule, hard, , DARZALEX, REVLIMID
Assistance Publique - Hôpitaux de Paris (AP-HP), Inca
multiple myeloma myelome multiple, myeloma myelome, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
COLUMBA, NCT03277105 / 2017-000206-38: A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Checkmark Approved in Canada based on COLUMBA and PLEIADES study in four regimens for 1L r/r multiple myeloma with transplant-ineligible patients
Aug 2020 - Aug 2020: Approved in Canada based on COLUMBA and PLEIADES study in four regimens for 1L r/r multiple myeloma with transplant-ineligible patients
Checkmark Approved based on COLUMBA study as monotherapy for 3L multiple myeloma including PI and an immunomodulatory agent or double-refractory to a PI and an immunomodulatory agent in South Korea
Jul 2020 - Jul 2020: Approved based on COLUMBA study as monotherapy for 3L multiple myeloma including PI and an immunomodulatory agent or double-refractory to a PI and an immunomodulatory agent in South Korea
Checkmark Approved based on COLUMBA study in combination with bortezomib+halidomide+dexamethasone for 1L multiple myeloma eligible for autologous stem cell transplant in South Korea
More
Completed
3
522
Europe, Canada, Japan, US, RoW
Dara SC, Dara IV, JNJ-54767414
Janssen Research & Development, LLC
Multiple Myeloma
06/19
01/24
CANDOR, NCT03158688 / 2016-003554-33: Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Checkmark Primary analysis results from CANDOR trial for r/r multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: Primary analysis results from CANDOR trial for r/r multiple myeloma at ASH 2019
Checkmark From CANDOR trial in combination with carfizomib & dexamethasone for r/r multiple myeloma
Sep 2019 - Sep 2019: From CANDOR trial in combination with carfizomib & dexamethasone for r/r multiple myeloma
Completed
3
466
Europe, Canada, Japan, US, RoW
Dexamethasone, Daratumumab, DARZALEX®, Carfilzomib, KYPROLIS®
Amgen
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
07/19
04/22
MAXDARA, NCT03792620: Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation

Unknown status
3
20
RoW
Cyclo Thal Dex Daratumumab, CTD-Dara,
Grupo de Estudos Multicentricos em Onco-Hematologia
Multiple Myeloma Stage I
05/20
04/22
OCTANS, NCT03217812: A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Completed
3
220
RoW
Velcade, Bortezomib, Melphalan, Prednisone, Daratumumab, JNJ-54767414
Janssen Research & Development, LLC
Multiple Myeloma
07/20
03/24
The APOLLO Study, NCT03180736 / 2017-001618-27: Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone

Checkmark Submitted in EU in combination with pomalidomide/dexamethasone for relapsed/refractory multiple myeloma
Nov 2020 - Nov 2020: Submitted in EU in combination with pomalidomide/dexamethasone for relapsed/refractory multiple myeloma
Checkmark Filed in US in combination with pomalidomide/dexamethasone for relapsed/refractory multiple myeloma
Nov 2020 - Nov 2020: Filed in US in combination with pomalidomide/dexamethasone for relapsed/refractory multiple myeloma
Checkmark From trial in combination with pomalidomide/dexamethasone for multiple myeloma
More
Active, not recruiting
3
304
Europe, RoW
Daratumumab, Pomalidomide, Dexamethasone
European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
07/20
06/22
Cassiopeia, NCT02541383 / 2014-004781-15: A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

Checkmark Data from second part of CASSIOPEIA study in multiple myeloma
Oct 2020 - Oct 2020: Data from second part of CASSIOPEIA study in multiple myeloma
Checkmark From CASSIOPEIA trial at ASCO 2019
Jun 2019 - Jun 2019: From CASSIOPEIA trial at ASCO 2019
Checkmark From CASSIOPEIA trial multiple myeloma at EHA 2019
More
Active, not recruiting
3
1085
Europe
Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD), Arm A Part 1, Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab, Arm B Part 1, Daratumumab, Arm B Part 2
Intergroupe Francophone du Myelome, HOVON - Dutch Haemato-Oncology Association, Janssen Research & Development, LLC
Multiple Myeloma
08/20
06/23
2019-002147-20: A randomised trial of Daratumumab to remove myeloma cells from blood stem cells before an autograft for patients with multiple myeloma

Not yet recruiting
3
338
Europe
Neosar, Darzalex, Mozobil, Melphalan, Neupogen, Plerixafor, Melphalan, G-CSF, Powder for solution for injection/infusion, Solution for injection, Powder and solvent for solution for injection/infusion, Neosar, Darzalex, Mozobil, Melphalan, Neupogen
University of Birmingham, Leuka, Anthony Nolan, NHSBT, Janssen-Cilag Limited
Newly diagnosed Multiple Myeloma (MM), Blood cancer, Diseases [C] - Cancer [C04]
 
 
2021-001005-67: Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy Allogene Stammzelltransplantation im Vergleich zur konventionellen Therapie als Salvage-Therapie für Patienten mit rezidiviertem / progredientem Multiplem Myelom nach der Erstlinientherapie

Not yet recruiting
3
482
Europe
human allogeneic hematopoietic stem cells from peripheral blood stem cell collections, human autologous stem cells, DARZALEX® 20 mg/ml, Suspension for injection, Powder and solvent for concentrate for solution for infusion, Solution for injection, Capsule, hard, Concentrate and solvent for solution for infusion, , Powder for solution for injection, Powder for injection, Tablet, human allogeneic hematopoietic stem cells (allo-HSC) from peripheral blood stem cell (PBSC) collections, autologous stem cells, Kyprolis®, DARZALEX® 1 800 mg Injektionslösung, NINLARO®, Empliciti®, IMNOVID, DARZALEX® 20 mg/ml, REVLIMID® Hartkapseln, VELCADE 3,5 mg Pulver, Bortezomib medac 3,5 mg, Fortecortin® Inject, Fortecortin®
University Medical Center Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA)
Multiple myeloma, cancer that forms in a type of white blood cell called a plasma cell, Diseases [C] - Cancer [C04]
 
 
2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Not yet recruiting
3
750
Europe, RoW
Bortezomib, Dexamethasone, Ciltacabtagene Autoleucel, Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), Lenalidomide, JNJ-68284528, JNJ-54767414, Powder for solution for injection, Coated tablet, Dispersion for infusion, Injection, Capsule, hard, Solution for injection, VELCADE, Dexamethasone, CARVYKTI, lenalidomide accord, DARZALEX
Stichting European Myeloma Network (EMN), European Myeloma Network (EMN), Janssen-Cilag International NV
Multiple Myeloma, Newly diagnosed multiple myeloma, Diseases [C] - Cancer [C04]
 
 
2021-000803-20: MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Transplant-Ineligible Participants With Newly-Diagnosed Multiple Myeloma

Ongoing
3
646
Europe
Elranatamab, Daratumumab, Lenalidomide 5 mg, Dexamethasone 20 mg, Lenalidomide 10 mg, Lenalidomide 15 mg, Lenalidomide 20 mg, Lenalidomide 25 mg, Dexamethasone 4 mg, PF-06863135, Solution for injection, Capsule, Tablet, DARZALEX 1800 mg solution for injection
Pfizer Inc., Pfizer, Inc.
Multiple myeloma, Hematological malignancy, Diseases [C] - Cancer [C04]
 
 
GEM2017FIT, NCT03742297 / 2017-000044-18: Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

Active, not recruiting
3
462
Europe
Lenalidomide., Carfilzomib, Bortezomib, Daratumumab, Dexamethasone, Prednisone, Melphalan
PETHEMA Foundation
Newly Diagnosed Multiple Myeloma
07/23
01/31
DREAMM 7, NCT04246047 / 2018-003993-29: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Calendar Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Jul 2023 - Dec 2023: Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jul 2023 - Dec 2023: Data readout from DREAMM-7 trial for 2L+ multiple myeloma
Jul 2023 - Dec 2023: Acceptance of regulatory submissions in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
More
Active, not recruiting
3
571
Europe, Canada, Japan, US, RoW
Belantamab mafodotin, Daratumumab, Bortezomib, Dexamethasone
GlaxoSmithKline
Multiple Myeloma
10/23
06/26
DARVIVA, NCT06296121: A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

Recruiting
3
252
RoW
BCD-264, daratumumab, Darzalex
Biocad
Multiple Myeloma
01/25
07/26
FUMANBA-03, NCT06464991: A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM

Recruiting
3
240
RoW
Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone
Nanjing IASO Biotechnology Co., Ltd.
Multiple Myeloma
08/27
12/30
NCT06182774: Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Recruiting
3
559
Canada
Daratumumab, Lenalidomide, Dexamethasone
Canadian Cancer Trials Group, Canadian Institutes of Health Research (CIHR), Myeloma Canada
Multiple Myeloma
01/32
07/32
HOVON174MM, NCT06187441: FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone

Recruiting
3
599
Europe
Daratumumab Injection, Dexamethasone, Lenalidomide capsule
Stichting Hemato-Oncologie voor Volwassenen Nederland
Multiple Myeloma
01/31
12/37
NCT03836014: Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Active, not recruiting
3
436
Europe
Daratumumab/Lenalidomide/Dexamethasone for 24 months, Daratumumab/Lenalidomide/Dexamethasone until progression
Assistance Publique - Hôpitaux de Paris
Multiple Myeloma in Relapse
07/24
07/26
iMMagine-3, NCT06413498: A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants with Relapsed/ Refractory Multiple Myeloma

Recruiting
3
450
US
Anitocabtagene Autoleucel, CART-ddBCMA, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib
Kite, A Gilead Company, Arcellx, Inc.
Multiple Myeloma
07/28
07/31
NCT04288765: Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

Withdrawn
3
0
RoW
Daratumumab Only Product in Parenteral Dose Form, Lenalidomide, Carfilzomib, Dexamethasone
Grupo Cooperativo de Hemopatías Malignas
Multiple Myeloma
12/24
02/25
NCT06615479: A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)

Not yet recruiting
3
440
Europe, Canada, Japan, US, RoW
BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Celgene Corporation
Relapsed or Refractory Multiple Myeloma (RRMM)
12/27
07/32
Perseus, NCT03710603 / 2018-002992-16: Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

Hourglass Jan 2022 - Dec 2022 : From PERSEUS trial in combination with Darzalex for 1L multiple myeloma
Checkmark Approved based on COLUMBA study in combination with bortezomib+halidomide+dexamethasone for 1L multiple myeloma eligible for autologous stem cell transplant in South Korea
Jul 2020 - Jul 2020: Approved based on COLUMBA study in combination with bortezomib+halidomide+dexamethasone for 1L multiple myeloma eligible for autologous stem cell transplant in South Korea
Active, not recruiting
3
690
Europe, RoW
Daratumumab, velcade (bortezomib), lenalidomide, dexamethasone, velcade, bortezomib, Lenalidomide
European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
05/25
11/29
CEPHEUS, NCT03652064 / 2018-001545-13: A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Hourglass Jan 2023 - Dec 2023 : Data from CEPHEUS trial for transplant ineligible frontline multiple myeloma
Active, not recruiting
3
395
Europe, Canada, Japan, US, RoW
Daratumumab, JNJ-54767414, DARZALEX, Bortezomib, Velcade, Lenalidomide, Revlimid, Dexamethasone
Janssen Research & Development, LLC
Multiple Myeloma
08/25
01/27
NCT05438043: A Study of Daratumumab

Recruiting
3
500
Europe, US, RoW
Daratumumab, JNJ-54767414, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide
Janssen Research & Development, LLC
Multiple Myeloma
01/26
04/26
NCT05776940: Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis

Not yet recruiting
3
116
NA
Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab, Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules + Routine therapy, Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab, Routine therapy
Air Force Military Medical University, China
Immunoglobulin Light-chain Amyloidosis
03/26
03/26
MRD-CONFIRM, NCT05203003: Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

Recruiting
3
260
Europe
Assessment of MRD
Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
04/27
12/28
KarMMa-3, NCT03651128 / 2018-001023-38: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Oct 2022 - Dec 2023: Approval in US for 3-5L multiple myeloma
Hourglass Jun 2023 - Jun 2023 : Subgroup analysis of outcomes for patients with high-risk r/r multiple myeloma from the KarMMa-3 trial at EHA 2023
Checkmark Data from KarMMa-3 trial for 3L multiple myeloma
Aug 2022 - Aug 2022: Data from KarMMa-3 trial for 3L multiple myeloma
Active, not recruiting
3
381
Europe, Canada, Japan, US
bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab
Celgene
Multiple Myeloma
04/27
04/27
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
MagnetisMM-6, NCT05623020 / 2021-000803-20: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Recruiting
3
966
Europe, Canada, Japan, RoW
Elranatamab, Daratumumab, Lenalidomide, Dexamethasone
Pfizer, Pfizer, Inc.
Multiple Myeloma
03/28
11/31
DETER-SMM, NCT03937635: Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Recruiting
3
288
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Smoldering Plasma Cell Myeloma
12/29
12/29
ChiCTR2400084921: A Phase III Randomized, controlled study of Equecabtagene Autoleucel Injection in Subjects with Lenalidomide-Refractory RRMM (Relapse/Refractory Multiple Myeloma)

Recruiting
3
240
 
Equecabtagene Autoleucel Injection; DPd(Daratumumab, Pomalidomide, Dexamethasone) or PVd (Pomalidomide, Bortezomib, Dexamethasone)
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences; Nanjing IASO Medical Technology Co., Ltd., Completely self-supporting
Multiple myeloma
 
 
NCT02419118 / 2014-005189-31: "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "

Completed
2/3
4
Europe
Daratumumab, CD38 monoclonal antibody, HuMax CD38, Lenalidomide, Dexamethasone
Vejle Hospital
Multiple Myeloma
10/15
10/15
NCT03357952 / 2017-002611-34: A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Checkmark Recommendation by DMC for discontinuation of MMY2036 study
May 2018 - May 2018: Recommendation by DMC for discontinuation of MMY2036 study
Completed
2/3
10
Europe, RoW
Daratumumab, JNJ-54767414, JNJ-63723283
Janssen Research & Development, LLC
Multiple Myeloma
10/18
11/21
2019-004401-27: The REMNANT (RElapse from Mrd Negativity As iNdication for Treatment) study

Not yet recruiting
2/3
391
Europe
Velcade, Revlimid, Dexamethasone, Darzalex, Kyprolis, Powder for injection, Tablet, Concentrate for solution for infusion, Powder for solution for infusion, Velcade, Revlimid, Darzalex, Kyprolis
Oslo University Hospital, Department of Hematology, Oslo University Hospital
Multiple myeloma, Multiple myeloma, Diseases [C] - Cancer [C04]
 
 
DAWN, NCT05403138: Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders

Recruiting
2/3
72
RoW
Daratumumab, Darzalex, Placebo
Tianjin Medical University General Hospital
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
08/24
10/24
REMNANT, NCT04513639: The Relapse From MRD Negativity as Indication for Treatment () Study

Recruiting
2/3
176
Europe
Early treatment of relapse with carfilzomib, dexamethasone, daratumumab, DKd, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab
Oslo University Hospital, St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, University Hospital, Akershus, Helse Stavanger HF, Førde Central Hospital, Sorlandet Hospital HF, Nordlandssykehuset HF, The Hospital of Vestfold, Helse Nord-Trøndelag HF, Alesund Hospital, Sykehuset Ostfold
Multiple Myeloma
06/31
06/32

Download Options